Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRX5183 in Relapsed/Refractory AML and High Risk MDS
NCT02749708Phase 1Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2017
- Primary completion
- Aug 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of irx-5183 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (3 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Recommended Phase 2 Dose at 2 years and Overall Response Rate at 2 years. Started Jan 2017; status: terminated.
02
Drugs
irx-5183
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT02749708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02749708.